Ascott Residence Trust – Stability through asset recycling and redevelopments February 5, 2020 1344

PSR Recommendation: BUY Status: Upgraded
Target Price: S$1.53
  • 4Q19/FY19 NPI and DPU in line with forecast.
  • Diversified portfolio proving resilient, active portfolio reconstitution unlocked c.S$200mn of net gains.
  • The longer average length of stays typical for serviced residence, driven by corporate clientele makes ART less affected by Coronovirus impact compared to leisure-driven hospitality REITs.
  • Upgrade to BUY with a higher TP of $1.53 due to higher earnings/DPU forecast and factoring in recent divestments and the redevelopment of Somerset Liang Court.

 

The Positives

  • Revenue and gross profit stable, minor fluctuations due to asset recycling deemed normal. ART’s diversified portfolio kept earnings stable, with better performance in certain counties, (Philippines, Belgium, Singapore, Vietnam) offsetting softer markets (Australia, China, Japan) which experienced strong competition. Highly accretive asset recycling caused a minor dip in earnings but overall beneficial to unitholders and normal in the course of business. Figure 1 summarises the notable events in FY19.
  • Active portfolio reconstitution unlocked S$200mn in net gains which were reinvested into higher-yielding assets. In 2019 ART divested Ascott Raffles Place, Somerset West Lake Hanoi, partial sale of Somerset Liang Court, Citadines Xinghai Shuzhou and Citadines Zhuakou Wuhan. Ascott RP was divested at an exit yield of 2%, 64.3% above book value, with net gains of c.S$135mn which were partially reinvested into Citadines Connect Sydney Airport (CCSA) (EBITDA yield of c.6%). The sales of the two Citadines assets in China at an exit cap rate of c.3.7%, >30% above book value, will reap net gains of c.S$21.2mn and is expected to be completed in 1H20. The partial sale of the Somerset Liang Court asset and at 4% above book value would yield S$84.3mn revaluation gains, S$49.8mn of which will be realised upon completion of the sale in April 2020, while the remaining S$42.8mn would be tied to the retained land which will be redeveloped as part of the proposed integrated development at Liang Court (stabilised yield of c.4%).
  • Cost of borrowing was fell 10bps to 2% p.a. ART refinanced S$150mn 5% of perps with S$150mn 3.88% perps in September 2019, capturing c.S$1.7mn in savings. A second tranche of S$250mn 3.86% perps are callable in June 2020 and we believe ART will once again capitalise on the opportunity to refinance their perps at a lower coupon.

The Negatives

  • 4Q19 revenue fell 1.8% YoY due to divestments, but gross profit grew 3%. Divestment of Ascott RP and Somerset Hanoi resulted in lower 4Q19 revenue, partially offset by contribution from CCSA. Though the divestment and acquisition of Ascott RP and CCSA were both timed to occur in May 2019, CCSA’s contribution would only partially offset the loss of income from Ascott RP given that it is a smaller asset. Higher 4Q19 gross profit was supported by better performance in the Philippines (+42%), Belgium (+38%), Singapore (+20%) and Vietnam (+7%).

Outlook

The merger with Ascendas Hospitality Trust was completed 31 December and will contribute to ART’s portfolio from 1 January 2020. Figure 2 and 3 show the breakdown of ART’s gross revenue by geography and lease type with the contribution from AHT’s master leases assets in Japan (5), Korea (2) and Singapore (1) and management contract assets in Australia (6).

Inclusion into the FTSE Nareit Developed Index is likely given that ART has met the criteria for inclusion.

Impact of the Novel Coronavirus

The management expects that travel volumes will be impacted in the short-term, as well as some cancellation of bookings. However, given ART has more long-term stays than short-term stays which are driven by corporate clients on project groups or secondment and less leisure-tourism dependent, we expect to be more protected than other hospitality REITs. Figure 4 shows the average length of stay at their accommodations by country, which ranges 1 to 7 months.

Upgrade to BUY with a higher target price of $1.53 (prev. $1.36).

Our forecast includes the contributions from the AHT portfolio as well the announced divestments of Somerset Hanoi, partial divestment and redevelopment of Somerset Liang Court and the divestment of the 2 Citadines assets in China. The recent collapse in the share price due to the uncertainty caused by the Novel Coronavirus presents a good entry price, in our opinion. We upgrade our recommendation to BUY from ACCUMULATE. ART is trading at an attractive yield of 6.6% and P/NAV of 0.94.

Important Information

This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.

By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.

The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.

This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.

Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.

Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.

To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.

IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE

Where the report contains research analyses or reports from a foreign research house, please note:

  1. recipients of the analyses or reports are to contact Phillip Securities Research (and not the relevant foreign research house) in Singapore at 250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101, telephone number +65 6533 6001, in respect of any matters arising from, or in connection with, the analyses or reports; and
  2. to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, Phillip Securities Research accepts legal responsibility for the contents of the analyses or reports.
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

Get access to all the latest market news, reports, technical analysis
by signing up for a free account today!